Abstract P6-10-02: Assessing biomarkers to inform treatment de-escalation: Mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 Trial
Sara J. Venters(University of California, San Francisco), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Jodi M. Carter(University of Alberta), Lamorna Brown Swigart(University of California, San Francisco), Laila Khazai(Moffitt Cancer Center), Sunati Sahoo(The University of Texas Southwestern Medical Center), Kimberly Cole(Yale University), Jane Wei(University of California, San Francisco), Yunn‐Yi Chen(University of Vermont), Amy L. Delson(Children's Advocacy Center), Christina Yau(Hospital Authority), Dina Kokh(University of Alabama at Birmingham), Bev Parker(Children's Advocacy Center), Laura J. Esserman(University of California, San Francisco), Ronald Balassanian, Gregor Krings(Cleveland Clinic), Molly Klein(University of Minnesota), Laura J. van’t Veer(University of California, San Francisco), Denise M. Wolf
Cited by 7
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k